BioStock: Evaxion receives phase IIb go-ahead from FDA

Evaxion Biotech started 2022 with a green light from the Australian authorities to conduct a phase IIb study with lead drug candidate EVX-01 in metastatic melanoma. 2023 for the Danish immunotherapy company begins with the FDA-approval to expand the phase IIb study to the US. BioStock contacted CEO Per Norlén to learn more about what this means for the project.

Read the interview with Per Norlén at biostock.se:

Evaxion receives phase IIb go-ahead from FDA - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/